Neuroendocrine Tumor
📧 Sign up to get email alerts when something new happens for Neuroendocrine Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-04-22Clinical Trial Update: 18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis
A clinical trial evaluating an 18F-labeled FAP-targeted molecular imaging probe for early tumor diagnosis is currently recruiting.
-
CLINICAL_TRIALS research · 2025-04-03Clinical Trial Update: Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
This clinical trial update describes the REBORN study, which aims to identify biomarkers for diagnosing neuroendocrine tumors and assessing …
-
CLINICAL_TRIALS research · 2025-04-02Clinical Trial Update: Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/Phase 2 study comparing radiopharmaceutical tracers Al18F-NOTA-LM3, 68Ga-DOTATATE, and 68Ga-N…
-
FDA approval · 2025-03-28FDA Approved: LOCAMETZ — Supplemental Application (Advanced Accelerator Applications USA, Inc)
FDA approved a supplemental application for LOCAMETZ to include a kit for the preparation of Gallium-68 gozetotide for PET imaging.
-
CLINICAL_TRIALS research · 2025-03-27Clinical Trial Update: The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study
A multicenter Australia-New Zealand trial evaluating endoscopic tissue resection for upper gastrointestinal cancers; currently recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-03-14Clinical Trial Update: Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE) [Phase 2]
A Phase 2 clinical trial is evaluating a triple combination of sintilimab, IBI310, and surufatinib for high-grade neuroendocrine tumors and …
-
EMA approval · 2025-03-10EMA Authorised: Sutent (sunitinib) — Pfizer Limited
Sutent (sunitinib) has been authorised by the EMA with indications for gastrointestinal stromal tumor, renal cell carcinoma, and neuroendocr…
-
CLINICAL_TRIALS research · 2025-03-03Clinical Trial Update: Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial [Phase 2, Phase 3]
A clinical trial update for the ATSA trial evaluating absorbed tumor dose in peptide receptor radionuclide therapy using long-acting somatos…
-
CLINICAL_TRIALS withdrawal · 2025-02-25Clinical Trial Update: Study of rSIFN-co for Patients With Advanced Solid Tumors [Phase 1]
A Phase 1 clinical trial of rSIFN-co for advanced solid tumors has been terminated, involving malignancies including melanoma, kidney cancer…
-
CLINICAL_TRIALS trial_result · 2025-02-12Clinical Trial Update: A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO) [Phase 2]
Phase 2 diagnostic imaging trial evaluating copper-64 SARTATE for PET imaging in patients with known or suspected neuroendocrine tumors has …
-
CLINICAL_TRIALS trial_result · 2025-02-12Clinical Trial Update: Preoperative Imaging in Patients With Small Bowel Neuroendocrine Tumors
This clinical trial update reports on preoperative imaging in patients with small bowel neuroendocrine tumors, including those with lymph no…
-
CLINICAL_TRIALS withdrawal · 2025-02-10Clinical Trial Update: Neuroendocrine and Adrenal Tumors
The clinical trial NCT04432532 investigating neuroendocrine tumors and adrenal tumors has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2025-02-06Clinical Trial Update: Dual-Tracer Theranostic PET [NA]
Clinical trial update on dual-tracer theranostic PET imaging for neuroendocrine tumors and prostate cancer; results have been posted.
-
CLINICAL_TRIALS trial_result · 2025-01-31Clinical Trial Update: Cabozantinib and Nivolumab for Carcinoid Tumors [Phase 2]
A Phase 2 study evaluating the combination of cabozantinib and nivolumab for carcinoid tumors has completed with results posted in January 2…
-
CLINICAL_TRIALS trial_result · 2025-01-27Clinical Trial Update: Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors [Phase 2]
A Phase 2 trial evaluating Olaparib plus Durvalumab in EGFR-mutated non-small cell lung cancer that transformed to small cell lung cancer an…
-
CLINICAL_TRIALS research · 2025-01-14Clinical Trial Update: Use of 68Ga-DOTATOC PET/CT-enterography for Detection of the Primary Lesion in Neuroendocrine Tumors of the Small Bowel [NA]
This clinical trial evaluates whether 68Ga-DOTATOC PET/CT-enterography can detect the primary lesion in small bowel neuroendocrine tumors, a…
-
CLINICAL_TRIALS trial_result · 2025-01-13Clinical Trial Update: Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. [Phase 2]
This is a phase 2 trial evaluating the combination of platinum-doublet chemotherapy with nivolumab for gastroenteropancreatic neuroendocrine…
-
CLINICAL_TRIALS trial_result · 2025-01-13Clinical Trial Update: Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors [Phase 1, Phase 2]
The document reports a completed Phase 1/Phase 2 trial evaluating Lutetium-177 dotatate in combination with metronomic capecitabine for aggr…
-
CLINICAL_TRIALS trial_result · 2025-01-06Clinical Trial Update: Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver [Phase 2]
Phase 2 randomized trial evaluating embolization for liver metastases from malignant neuroendocrine tumors has completed enrollment; the stu…
-
CLINICAL_TRIALS trial_result · 2024-12-24Clinical Trial Update: Avelumab in G2-3 NET [Phase 2]
A Phase 2 trial of avelumab in patients with grade 2-3 neuroendocrine tumors has completed.
-
CLINICAL_TRIALS trial_result · 2024-12-17Clinical Trial Update: United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting
A completed UK patient-preference study evaluated Somatuline Autogel (lanreotide) and treatment administration settings for neuroendocrine t…
-
CLINICAL_TRIALS trial_result · 2024-12-09Clinical Trial Update: Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients [Phase 2]
This Phase 2 clinical trial compares dosimetry-guided PRRT using Lu-177-DOTATOC to standard-dose PRRT in neuroendocrine neoplasm patients. T…
-
CLINICAL_TRIALS research · 2024-12-03Clinical Trial Update: Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors
An ongoing observational cohort study by Hospices Civils de Lyon examining the development and progression of carcinoid heart disease in adu…
-
CLINICAL_TRIALS trial_result · 2024-11-26Clinical Trial Update: Phase 2 Study of ONC201 in Neuroendocrine Tumors [Phase 2]
Phase 2 study of ONC201 in recurrent or metastatic neuroendocrine tumors has completed enrollment with results posted on 2024-11-26.
-
CLINICAL_TRIALS research · 2024-11-18Clinical Trial Update: Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study [Phase 2]
This clinical trial update notes a Phase 2 study evaluating metronomic temozolomide in unfit patients with advanced neuroendocrine tumors (N…